You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Belgium

Jun 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Slight but fragile recovery in 2011

After the slowdown of 2010, sales of consumer health products recovered slightly in 2011. Nonetheless, many players were disappointed as growth remained below-average compared with the CAGR of the review period. This stemmed from a limited number of diseases and a low level of consumer confidence. By contrast with the bulk of the review period, consumers tended to make a trade-off between superfluous products and what really mattered. Marketers also faced increasingly tough juridical constraints or medical surveys regarding product claims, even within the most promising niches.

Negative environment for consumer health affects sales

The most notable event – and probably a key factor in the too-weak recovery of the market – was a return to a rather negative climate surrounding consumer health. While the Belgian authorities seemed to accept more positive switches (alli and H2 blockers for instance) in recent years, deregulation slowed down in 2011with the questioning of paediatric dextromethorphan products by the Commission des Médicaments (Medicines Commission) – although of the positive switch of PPIs is still forecast for 2012 or 2013. Moreover, there were negative experts’ opinions at the end of 2011 about the harmlessness of blockbuster ingredients or brands such as acetaminophen and the Motilium brand from Janssen-Cilag. The negative results of some medical surveys and the recommendations of the EFSA (European Food Safety Authority) hampered the potential of some products in vitamins and dietary supplements and in weight management.

Disparate results in a still fragmented competitive environment

In spite of some improvements in recent years, legislation regarding registration, pricing, distribution and advertising in Belgium was still less favourable to manufacturers than in the majority of Western European countries. Therefore, the competitive environment was still characterised by a high level of fragmentation in 2011, with no clear leader. The top 10, which mainly encompassed ethical and OTC-registered remedy specialists, experienced disparate results in 2011. The leader Janssen-Cilag levelled out, notably due to frequent changes of management and strategies. Usually more innovative and dynamic than multinationals, local players also registered mixed results, with the exception of the leading Belgian GBO Omega Pharma, which performed strongly in 2011.

Distribution remains under the control of pharmacies despite some changes

As in France, chemists/pharmacies monopolised sales of standard analgesics, digestive remedies, NRT smoking cessation aids and eye care products despite rumours of deregulation during the second half of the review period. This channel also held a dominant share in all other categories. This dominance left little room for other distribution channels, the most important being grocery retailers. From a low base, parapharmacies/drugstores gained ground in recent years by virtue of the dynamism of the Dutch chain Kruidvat and the emergence of new chains in parapharmacies. In the modest non-store retailing channel, internet retailing was the main growth driver, mainly since the launch of online pharmacies such as newpharma.be.

Bleak prospects overall

Many players are pessimistic about the outlook for consumer health. The prospect of another debt crisis could dampen consumer spending and affect sales of non-essential products. In combination with the more stringent recommendations from the EFSA and some negative medical surveys and experts’ opinions, it could result in the stagnation of consumer health in constant value terms over the forecast period.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Belgium with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Belgium, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Belgium for free:

The Consumer Health in Belgium market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Belgium?
  • What are the major brands in Belgium?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in Belgium - Industry Overview

EXECUTIVE SUMMARY

Slight but fragile recovery in 2011

Negative environment for consumer health affects sales

Disparate results in a still fragmented competitive environment

Distribution remains under the control of pharmacies despite some changes

Bleak prospects overall

KEY TRENDS AND DEVELOPMENTS

Fragile economic recovery to result in a temporary improvement

Authorities and medical experts blow hot and cold

More health & wellness, certainly, but also more realism

Remedies for increasingly stressful lifestyles

Brand equity to remain the key in a restricted environment

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Penetration of Private Label by Category 2006-2011
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Vitamins and dietary supplements – registration and classification

Switch climate

Self-medication and preventative medicine

Generics

Switches

  • Summary 1 OTC – Switches 2009-2011

SOURCES

  • Summary 2 Research Sources

Consumer Health in Belgium - Company Profiles

Laboratoires Pharmaceutiques Trenker SA in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND AND PRODUCTION

COMPETITIVE POSITIONING

  • Summary 5 Laboratoires Pharmaceutiques Trenker: Competitive Position 2011

Laboratoria Qualiphar NV SA in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND AND PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Qualiphar NV SA, Laboratoria: Competitive Position 2011

Omega Pharma NV in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 11 Omega Pharma NV: Production Statistics

COMPETITIVE POSITIONING

  • Summary 12 Omega Pharma NV: Competitive Position 2011

Patch Pharma SA in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND AND PRODUCTION

COMPETITIVE POSITIONING

Tilman NV SA in Consumer Health (Belgium)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 17 Tilman NV SA: Competitive Position 2011

Adult Mouth Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • After several difficult years, adult mouth care seemed to make it through a bad patch. Before 2011, the category suffered from growing competition from standard mouthwash brands, which are included in beauty and personal care. Indeed, Pfizer and Colgate-Palmolive saw unexploited potential in this area, and reactivated their brands from 2008. In 2010 and during the first months of 2011, Listerine recorded double-digit current value growth. However, value sales of Listerine and Colgate Plax collapsed in the second half of the year due to the promotions for private label products.

SWITCHES

COMPETITIVE LANDSCAPE

  • Pfizer drove sales in adult mouth care in 2011 with almost half of category value sales. The popularity of its flagship Hextril brand resulted in a high level of self-medication. However, from the middle of the review period until mid-2011 at least, Pfizer focused on Listerine, the leading brand in standard mouthwash which contributed to the slowdown of Hextril in recent years.

PROSPECTS

  • Mouthwash has never been a dynamic category and is not expected to fare better in coming years. Unless there is another entrant with a strong advertising campaign, or the launch of a revolutionary concept, sales of adult mouth care are expected to decline by 5% in constant value terms over the forecast period.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2006-2011
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 14 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 15 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in Belgium - Category Analysis

HEADLINES

TRENDS

  • Industry consensus was that the end of 2010 and 2011 were atypically dynamic in terms of innovation. Novelties were interesting, including notably Dafalgan Agrume Effervescent, smaller variants of Dafalgan. It enabled manufacturers to offset a rather disappointing year in terms of infectious diseases. After the very cold autumn of 2010 enabled that year to end better than initially expected, the number and strength of infectious diseases was low in 2011: the winter was mild, the spring was warm and the autumn started with very hot temperatures. However, July and August were atypically rainy and cool.

SWITCHES

COMPETITIVE LANDSCAPE

  • UPSA Médica’s Dafalgan remained the leading brand in a concentrated competitive environment in 2011. The company recognised contenders such as Nurofen and mainly generics were more aggressive during the first half of 2011 and thus progressed better. However, UPSA Médica hoped to post more dynamic growth at the end of 2011 thanks to its innovations. The Dafalgan brand gained share over the review period by combining press and in-store campaigns and a semi-ethical approach to advertising. UPSA Médica also benefited from the remodelling of its sales force since 2008, amalgamating its OTC and Rx teams to work with both doctors and chemists/pharmacists. Dafalgan also benefited from the support of the European Back Association and EULAR (European League against Rheumatism) since 2008.

PROSPECTS

  • UPSA Médica’s promotional drive could revitalise the competition between the company and its main rival Boots Healthcare. Marketing support could help to restore the company’s growth trajectory after two years of slowdown. Furthermore, the deregulation of retail distribution of OTC analgesics, for example with internet sales, could fuel overall sales in coming years. Manufacturers of analgesics could benefit from increasing self-medication among Belgians. Consumers are increasingly seeking information about minor ailments on websites. Thus, they can avoid visiting a doctor in some cases by buying OTC analgesics without a doctor’s recommendations.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2006-2011
  • Table 19 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 21 Analgesics Company Shares by Value 2007-2011
  • Table 22 Analgesics Brand Shares by Value 2008-2011
  • Table 23 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in Belgium - Category Analysis

HEADLINES

TRENDS

  • According to most players, the main event in calming and sleeping products was the breakthrough of Metagenics Belgium’s Metarelax over the latter years of the review period. This brand and others, often herbal/traditional, grew on the back of the development of stress and insomnia given consumers’ increasingly hectic lifestyles. Such products are the first-step alternatives to Rx sedatives, while many Belgians still distrust Rx products and are wary of the danger of addiction.

SWITCHES

COMPETITIVE LANDSCAPE

  • In a rather fragmented competitive landscape, Metagenics Belgium became the category leader in 2010 and consolidated its position in 2011 owing its impressive expansion. By almost doubling its sales every year from the end of 2009, Metarelax was considered the most successful brand of the last couple of years of the review period in the overall consumer health market. The product comprises magnesium and other non-herbal ingredients.

PROSPECTS

  • Marketers are confident about the potential of calming and sleeping products. By virtue of the development of many products in parapharmacies/drugstores and even in grocery retailers, the level of self-medication should develop further. Although many consumers will still need the advice of pharmacists, the herbal or “foodstuff” nature of most calming and sleeping products should reassure consumers.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2006-2011
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 27 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 28 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in Belgium - Category Analysis

HEADLINES

TRENDS

  • In 2011 cough, cold and allergy (hay fever) remedies’ volume sales suffered as a result of “unfavourable” weather – after the cold autumn of 2010, the winter and autumn seasons in 2011 were very mild, and the number of outbreaks of infectious diseases was lower than is typical. Also, many years after the questioning of combination cough, cold and allergy remedies – as a result of which most were withdrawn – the category was again questioned by the Commission des Médicaments, particularly paediatric variants.

SWITCHES

COMPETITIVE LANDSCAPE

  • The competitive landscape for cough, cold and allergy (hay fever) remedies was concentrated in terms of companies, although it was fragmented in terms of brands. The top five players, namely Procter & Gamble, Solinest, Novartis Consumer Health, Sanofi and Melisana achieved a value share of 40% in 2011. Given medicated confectionery is included in this category, Procter & Gamble led in 2011 with a 14% value share by virtue of the high profile and strong sales of its Vicks umbrella brand, which is present in many categories. However, excluding medicated confectionery, the leader was Novartis Consumer Health.

PROSPECTS

  • Like other mainstream categories, cough, cold and allergy (hay fever) remedies should benefit from slow and progressive deregulation, notably in distribution. In the short term the majority of products will still be sold through chemists/pharmacies, but marketers should nonetheless pay attention to the recent emergence of sales via the internet – authorised since January 2009.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 33 Sales of Decongestants by Category: Value 2006-2011
  • Table 34 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 36 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in Belgium - Category Analysis

HEADLINES

TRENDS

  • The main event in 2011 was the sudden questioning of Janssen-Cilag’s Motilium, the leading brand in digestive remedies. According to research by Luc Hondeghem, a Belgian pharmacologist, domperidon, the molecule of Motilium could kill hundreds of people every year with a sudden heart attack. While the US never accepted this product (even in the Rx market), Motilium became the leading local brand in Belgium and the leader if international analgesic blockbusters Dafalgan and Nurofen are excluded. However, Motilium could have caused the death of 3,200 consumers from 2000 according to Luc Hondeghem. Although Janssen-Cilag is countering the allegations, this could trigger off a scandal in the country.

SWITCHES

COMPETITIVE LANDSCAPE

  • Other than the leader, digestive remedies was rather fragmented in 2011. Janssen-Cilag led the way with 26% of value sales in 2011 – a share greater than the next four players combined. Janssen-Cilag (owned by Johnson & Johnson) has a portfolio of highly popular local brands, namely Motilium in antacids, Imodium in diarrhoeal remedies and, to a lesser extent, Touristil in motion sickness remedies. Its flagship Motilium brand largely monopolised the gastroprokinetic category owing to its efficiency, its anti-nausea properties, and its convenience, thanks to the launch of an instant format in the middle of the review period. However, both Motilium and Imodium waned in 2011 after success over the review period.

PROSPECTS

  • Industry sources are less optimistic about the scope for growth in digestive remedies than last year. The outlook for the category is uncertain. Thanks to the possible positive switch of “third-generation” antacids, PPIs that were only available on an Rx basis, Pantozol Control by Nycomed Christiaens and other PPIs with the same pantoprazole molecule should enter the Belgian market in 2012 or 2013. Nonetheless, marketers wonder if this emergence will represent a revolution for the category or a non-event. Many traditional antacids could suffer as a result of distrust among chemists/pharmacists, who perceive these products as only treating the symptoms and less effective than OTC H2 blockers and PPIs.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 43 Digestive Remedies Company Shares by Value 2007-2011
  • Table 44 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • As a non-essential product, and due to renewed competition from cotton buds, ear care was affected by increasing price sensitivity among consumers.

SWITCHES

COMPETITIVE LANDSCAPE

  • With a 30% value share in 2011, Laboratoires Chauvin was the leading player thanks to its Cerulyx brand. Other players lagged far behind, and notably included Biologische Heilmittel Heel, Dolisos (a homeopathy specialist), Viatris and Sanofi.

PROSPECTS

  • Ear care products are perceived as non-essential products by consumers and this is not likely to change over the short term, sales of ear care are therefore expected to decline during this period. That said, the wave of more natural products still presents opportunities for ear care, and unit prices could recover in the second half of the forecast period. Thus, ear care is expected to increase by 3% in constant value terms over 2011-2016 to remain a small niche at €2 million at the end of the forecast period.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2006-2011
  • Table 48 Sales of Ear Care: % Value Growth 2006-2011
  • Table 49 Ear Care Company Shares by Value 2007-2011
  • Table 50 Ear Care Brand Shares by Value 2008-2011
  • Table 51 Forecast Sales of Ear Care: Value 2011-2016
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in Belgium - Category Analysis

HEADLINES

TRENDS

  • In 2011, various figures circulated about the number of terminations per year, in the region of 14,000. As a result there was still room for growth of both Rx and OTC emergency contraception products. OTC emergency contraception products did well until the launch of the Rx ellaOne from Laboratoires HRA Pharma after the authorisation by the European Medicines Evaluation Agency (EMEA) in 2009. This new brand focussed on the niche market of emergency contraception as it is effective for five days after sexual intercourse – while OTC products are effective for only three days. Even so, the product requires a doctor’s prescription and thus is more difficult to obtain, which limited the cannibalisation of OTC products by Rx ones.

COMPETITIVE LANDSCAPE

  • With 74% of value sales in 2011, NorLevo by Laboratoires HRA Pharma was the outright leading brand in emergency contraception. It is sold as a package with one blister of two tablets, each containing 0.75mg of levonorgestrel, a progestin. The product does not contain oestrogens and claims to have softer side effects than other brands on the market. Two pills are necessary for one treatment. Distributed by Besins International, NorLevo was the first brand available without prescription in Belgian chemists/pharmacies, from September 2001.

PROSPECTS

  • Early in 2011, a survey by doctors from the University of Nottingham showed that in the UK, sales of emergency contraception missed their aim of limiting pregnancies within young girls and women where such products were distributed for free or sold at a subsidised price. Even worse, STDs (Sexually Transmitted Diseases) progressed by 12% over the last decade in the UK.

CATEGORY DATA

  • Table 53 Sales of Emergency Contraception: Value 2006-2011
  • Table 54 Sales of Emergency Contraception: % Value Growth 2006-2011
  • Table 55 Emergency Contraception Company Shares by Value 2007-2011
  • Table 56 Emergency Contraception Brand Shares by Value 2008-2011
  • Table 57 Forecast Sales of Emergency Contraception: Value 2011-2016
  • Table 58 Forecast Sales of Emergency Contraception: % Value Growth 2011-2016

Eye Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • Cases of conjunctivitis took off during the first months of 2011 thanks to a warm spring but dropped drastically during the wet summer, which limited the distribution of pollen. As a result, allergy eye care declined by 3% in current value terms in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • In eye care the most dynamic players are often the most innovative, at the expense of old or non-innovative brands. Each novelty has the capacity to enable brand owners to quickly gain several percentage points of share at the expense of rivals. Following its introduction just prior to the review period, Théa Pharma’s Hyabak became the brand leader in 2006, and forged ahead during the bulk of the review period. Although Hyabak lost ground to Optive in 2008, it countered with an aggressive promotional campaign over 2009-2011 that enabled it to still to continue to gain share in 2011.

PROSPECTS

  • Regarding the capacity of Belgian consumers to self-medicate in the area of eye care, manufacturers have increasing doubts despite their efforts. Belgians accept directly buying vitamins, dietary supplements or cold, cough and allergy remedies when they are tired, stressed or have a cold. However, only a minority can purchase for the first time a brand in eye care without advice or a prescription from their ophthalmologist. Once the product has been prescribed once, they purchase it directly from pharmacists on an OTC basis. European deregulation enabled artificial tears to be sold through outlets other than chemists/pharmacies during the review period in Belgium. However, Belgians still depend on advice from chemists/pharmacists, and thus sales have not taken off in drugstores or supermarkets.

CATEGORY DATA

  • Table 59 Sales of Eye Care by Category: Value 2006-2011
  • Table 60 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 61 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 62 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 63 Eye Care Company Shares by Value 2007-2011
  • Table 64 Eye Care Brand Shares by Value 2008-2011
  • Table 65 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 66 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in Belgium - Category Analysis

HEADLINES

TRENDS

  • Some players interviewed spoke of the “calm before the storm”, others said 2011 was a good year for sales of herbal/traditional products. On the one hand, the imminent settlement of the European legislation regarding functional claims and dietary supplements hampered product launch activity in recent years. The prospect of questioning of herbal/traditional products made this category much less attractive in 2010. However, although there was a new law to limit claims by herbal products in May 2011, nothing concrete was settled and thus most players had a respite before the expected publication of banned substances and claims by the EFSA (European Food Safety Authority) in 2012 and 2013.

COMPETITIVE LANDSCAPE

  • With nearly 300 small laboratories offering at least one herbal brand and commanding marginal shares, herbal/traditional products had the most fragmented competitive landscapes. There was no clear leader in this category although Procter & Gamble and Solinest (distributor of Ricola in Belgium) were said theoretically to be leading players. However, herbal/traditional products specialists question this ranking, as this leadership stemmed from their medicated confectionery brands Vicks and Ricola. The top players were medium-sized operators, by virtue of sufficient flexibility to recognise the most promising concepts and invest in them quickly.

PROSPECTS

  • Some sources fear that the effects of the settlement of the European legislation regarding dietary supplements in the short term, more particularly with herbal ingredients, will freeze many new product development projects. A list of questioned substances is expected to be published. Manufacturers with products or ingredients on the list will have to indicate for each brand variant the necessary dose to be efficient, its effects and proof of its efficacy with tests and surveys. Once set up, even if the new legislation purges the category of its less credible brands, some manufacturers think that it would become increasingly difficult to attract new consumers without slightly audacious claims.

CATEGORY DATA

  • Table 67 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 68 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 69 Herbal/Traditional Products Company Shares 2007-2011
  • Table 70 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 71 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 72 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • Many products in medicated skin care are not considered crucial by consumers or face competition from reimbursed Rx products. Thus, sales of medicated skin care were affected directly by the economic crisis that hampered self-medication in this category in 2011 and consumers subsequently watching their budgets more closely. Moreover, the information campaigns regarding the danger of mycosis and other skin complaints, which began during the first half of the review period, were less effective in 2011 due to the cool and wet summer weather.

SWITCHES

COMPETITIVE LANDSCAPE

  • With a 15% value share Janssen-Cilag (owned by Johnson & Johnson) remained leader by a slight margin in 2011 in a competitive landscape less fragmented than in other categories. Janssen-Cilag was slightly ahead of Leo Pharmaceutical Products and Reckitt Benckiser. Janssen-Cilag owes its position to its Daktarin umbrella brand in antifungals and Nizoral, which led medicated shampoos.

PROSPECTS

  • Industry sources have strong reservations about the outlook for medicated skin care. On the one hand, the low level of consumer confidence and future purchasing power, and the limited marketing resources of some manufacturers are expected to discourage innovation in 2012. Some manufacturers confessed that they are likely to focus on more strategic categories or even Rx. On the other hand, the category encompasses a number of product areas that are sufficiently small that one key launch or the success of one particular brand could temporarily buoy overall medicated skin care sales. In addition, consumers want to take care more of their bodies and, owing to continuous information campaigns, more potential consumers will become aware of issues related to skin.

CATEGORY DATA

  • Table 73 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 74 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 75 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 76 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 77 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 78 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 79 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in Belgium - Category Analysis

HEADLINES

TRENDS

  • The most notable event of 2011 was the extension of the partial ban on smoking in restaurants and public places to the last bastions of horeca, namely cafés/bars and nightclubs. In early 2011, players in the category feared that the absence of government would have postponed again the settlement of more stringent legislation. However, in 2010 this laxity contributed to the recovery of sales of tobacco according to CRIOC (a consumer trade union), which declined over the whole decade. However, against all expectations, the smoking ban became total in the summer 2011, before the constitution of a government.

SWITCHES

COMPETITIVE LANDSCAPE

  • With a 45% value share, Janssen-Cilag NV was the leader in NRT smoking cessation aids in 2011. This stemmed from the acquisition of Nicorette in 2009. This brand concentrated successfully on modulable formats such as Nicorette Gum and Nicorette Microtab Lemon at a time when consumers were shifting towards more convenient smoking cessation aids. Nicorette’s strategy continued to pay off in 2011 as the product helped undecided and anxious smokers to reduce their consumption – a first step in increasing self-confidence before stopping for good.

PROSPECTS

  • At first sight, the ban on smoking in the last horeca establishments should give the category a boost. While the number of cafés/bars is expected to continue to decline in 2012, further smokers are likely to be tempted to quit. In addition, increased coverage in the press and on TV and the larger size of warnings on cigarette packs, with more direct warnings, such as “smoking kills”, should contribute to rising awareness of the damage smoking can do to health.

CATEGORY INDICATORS

  • Table 80 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 81 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 82 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 83 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 84 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 85 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 87 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

Sports Nutrition in Belgium - Category Analysis

HEADLINES

TRENDS

  • Due to the non-essential image of sports nutrition, a new financial crisis in 2011 could have been bad for the category. While manufacturers were resilient in terms of innovation and advertising and retailers ordered and stocked less in 2011 than in 2010, the demand was sustained by newcomers to sport and the loyalty of sportsmen who already purchased such products.

COMPETITIVE LANDSCAPE

  • The competitive environment in sports nutrition remained almost unchanged in comparison with previous years. Sales were still concentrated among the top three companies, which secured a 56% share of retail value sales in 2010. The remainder was fragmented, with many local, almost artisanal, players offering one or two products. Three players competed for leadership in 2011 – QNT, Nutrico and Twinlab-Inko.

PROSPECTS

  • A survey published by RTL (local TV chain) in 2011 showed that, even if the membership rates of gyms and fitness clubs progressed in recent years, the share of the population that frequented gym and fitness clubs was lower than in many Western European countries. In the middle of the review period, Belgium was behind the average European penetration rate of fitness centres, and even further behind the penetration rate in the US.

CATEGORY DATA

  • Table 88 Sales of Sports Nutrition: Value 2006-2011
  • Table 89 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 90 Sports Nutrition Company Shares 2007-2011
  • Table 91 Sports Nutrition Brand Shares 2008-2011
  • Table 92 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 93 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in Belgium - Category Analysis

HEADLINES

TRENDS

  • Opinions differ on the fortunes of vitamins and dietary supplements, and depend on the performance of brands. For the most optimistic, the crisis of 2009/10 interrupted several years of impressive growth but was followed by recovery. For others, the recovery of the first half of 2011 was fragile and vitamins and dietary supplements continued to experience below-average growth in 2011. This was due to the weak recovery of the local economy and the subsequent impact on consumer purchasing power, increasingly tough juridical constraints or medical surveys regarding product claims, even within the most promising niches. Products that used to drive growth before the crisis are more or less reaching maturity, including multivitamins or even probiotics or glucosamine that were still promising one or two years ago.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • There were no clear leaders setting trends in vitamins and dietary supplements, despite the presence of many dynamic brands. The competitive environment remained highly fragmented in 2011, the result of the presence of players from different backgrounds and countries and positioned in various distribution channels. The top five NBOs secured 32% of value sales of vitamins and dietary supplements in 2011.

PROSPECTS

  • Most players interviewed were cautious about the outlook for vitamins and dietary supplements. A legislation from the EFSA (European Food Safety Authority) regarding functional claims and dietary supplements could hamper the potential of some dynamic products. Manufacturers with products or ingredients included on this list will have to indicate for each brand variant the necessary dose to be efficient, the effects and proof of its efficiency with tests and surveys. If not, some substances and claims could be banned, such as amino acids for hair, potentially in the middle of the forecast period. Many other products could be affected by the legislation or be forced to revise their claims, including fish oil, magnesium and probiotics. In such cases, players may have to depend on high brand equity to offset the impact of the legislation.

CATEGORY DATA

  • Table 94 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 95 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 96 Dietary Supplements by Positioning 2006-2011
  • Table 97 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 98 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 99 Vitamins Brand Shares by Value 2008-2011
  • Table 100 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 101 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 102 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016
  • Summary 18 Dietary Supplements: Brand Ranking by Positioning 2010

Weight Management in Belgium - Category Analysis

HEADLINES

TRENDS

  • Weight management was governed by a new approach in 2011, namely weight control instead of weight loss. While a growing number of advocates and promoters (nutritionists and even women’s magazines) question diets, many Belgians wish to eat a healthier and more balanced diet, and avoid excess. Therefore manufacturers focused on snacks and more palatable products such as better-for-you bars rather than meal replacement products – Gerlinéa Delfiness, for example, which was relaunched in 2011 and included bars biscuits protein drinks. The aim of such products is to be considered alternatives to countlines and other snacks rather than “punishments”. These target people watching their weight and seeking good and healthy products to help meet this aim, rather than consumers wanting to lose weight. In weight loss supplements too, while consumers’ trust in fat burners dropped in 2011, the only products not to decline were appetite suppressants and fat catchers.

COMPETITIVE LANDSCAPE

  • Herbalife Belgium, Novartis Consumer Health and GlaxoSmithKline were the leaders in an increasingly concentrated landscape in 2011. With 25% of value sales in 2011, Herbalife Belgium was the leader by four percentage points in overall sales and the outright leader in direct selling. Traditional manufacturers and retailers often tended to underestimate the role of this channel, which enjoyed a strong peak of sales in 2009, notably due to the recruitment of more salespeople during the financial crisis. However, due to the decline of direct selling, Herbalife Belgium’s growth slowed down in 2011.

PROSPECTS

  • Three consecutive years of decline in weight management tend to underline that this category suffers from a structural decline that is expected to continue – rather than the negative impact of the weather. According to a key player, sales of slimming pills are less influenced by weather and seasons as typically consumers start diets in September or January. Omega Pharma tends to communicate at the end of the year in weight loss supplements, which indicates that seasonality is less important in this category.

CATEGORY DATA

  • Table 103 Sales of Weight Management: Value 2006-2011
  • Table 104 Sales of Weight Management: % Value Growth 2006-2011
  • Table 105 Weight Management Company Shares 2007-2011
  • Table 106 Weight Management Brand Shares 2008-2011
  • Table 107 Forecast Sales of Weight Management: Value 2011-2016
  • Table 108 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in Belgium - Category Analysis

HEADLINES

TRENDS

  • Current value growth in wound care slowed towards the end of the review period. With few exceptions, the most dynamic products in 2011 were value-for money and basic products, while the previous growth drivers of the category continued to wane. Manufacturers and retailers progressively withdrew such products from shelves in order to concentrate on more basic and value-for-money plasters. The high-tech niche of liquid plasters and haemostatic sprays, in sticking plasters/adhesive bandages, slumped as the novelty effect wore off and due to high unit prices, just as consumers became more selective and price sensitive.

COMPETITIVE LANDSCAPE

  • A well-established presence in both of the main distribution channels, with Hansaplast dominant in grocery retailers and Hansaplast Med in pharmacies, enabled Beiersdorf NV SA to lead the pack. With a 38% value share, Beiersdorf was the absolute leader in wound care in 2011. Already a leader in basic plasters, Beiersdorf focused on sticking plasters for feet and blisters in order to increase its share against Compeed (by W Pabisch NV), the leader of this segment. During the last couple of years, Beiersdorf suffered from the competition from Compeed, with its strong offensive in pharmacies, but as well from the aggressiveness of private label and low-cost products in grocery retailers. This led Beiersdorf to lose over 1 point share in 2011. In addition, with only updates of the already existing Hansaplast Med Bandage and Hansaplast Foot Care brand variants, Beiersdorf did not particularly innovate in 2011, which left the field clear for its competitors.

PROSPECTS

  • Marketers are less optimistic about the scope for development in wound treatment. The further penetration of private label products in the grocery channel and the ongoing decline of the most sophisticated products are expected to erode added value, unit prices and thus growth in the category over the forecast period. The most profitable top end of the wound treatments category is likely to see a slowdown in the context of economic recession in the short term.

CATEGORY DATA

  • Table 109 Sales of Wound Care by Category: Value 2006-2011
  • Table 110 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 111 Wound Care Company Shares by Value 2007-2011
  • Table 112 Wound Care Brand Shares by Value 2008-2011
  • Table 113 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 114 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Artichoke
            • Cranberry
            • Spirulina
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Lecithin
            • Other Other Non-Herbal Dietary Supplements
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Paediatric Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Paediatric Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Paediatric Consumer Health
      • Paediatric Analgesics
        • Paediatric Acetaminophen
        • Paediatric Aspirin
        • Paediatric Combination Products - Analgesics
        • Paediatric Diclofenac
        • Paediatric Dipyrone
        • Paediatric Ibuprofen
        • Paediatric Ketoprofen
        • Paediatric Naproxen
      • Paediatric Cough, Cold and Allergy Remedies
        • Paediatric Allergy Remedies
        • Paediatric Cough/Cold Remedies
      • Paediatric Digestive Remedies
        • Paediatric Diarrhoeal Remedies
        • Paediatric Indigestion and Heartburn Remedies
        • Paediatric Laxatives
        • Paediatric Motion Sickness Remedies
      • Paediatric Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Paediatric Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing
  • Smoking population - number of adult smokers
  • Smoking prevalence - % of adult population

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!